Xanthinuria: A Complete Guide for Patients
What is Xanthinuria?
Xanthinuria is a rare metabolic disorder characterized by an inability to properly break down the purine base xanthine. The defect occurs in the enzymatic pathway that converts purines (found in many foods and produced by the body) into uric acid, the final waste product that is normally excreted in the urine. Because the enzyme(s) are deficient or inactive, xanthine and its precursor hypoxanthine accumulate in the blood and are excreted in the urine, leading to low uric acid levels (hypouricemia) and, in some cases, formation of kidney stones made of xanthine.
There are two main inherited forms.
- Type I Xanthinuria: Deficiency of the enzyme xanthine oxidase (XO) alone.
- Type II Xanthinuria: Deficiency of both xanthine oxidase and aldehyde oxidase, a second enzyme that also participates in purine metabolism.
Both types are autosomal recessive, meaning a child must inherit a faulty gene from each parent to develop the condition. Acquired (non‑genetic) xanthinuria can also occur, usually as a result of certain medications or severe liver disease.
Common Causes
While hereditary forms are the most frequent, several other conditions or exposures can lead to a xanthinuric picture.
- Genetic mutations in the XDH gene: Loss‑of‑function mutations impair xanthine oxidase.
- Mutations in the MOCOS gene: Cause Type II by affecting the molybdenum cofactor needed for both XO and aldehyde oxidase.
- Allopurinol therapy: A medication used for gout that inhibits xanthine oxidase, raising xanthine levels.
- Febuxostat: Another XO inhibitor prescribed for hyperuricemia.
- Severe liver disease: Hepatic failure can reduce synthesis of the molybdenum cofactor.
- Molybdenum deficiency: Rare nutritional deficiency that impairs XO activity.
- High‑dose vitamin B12 (cobalamin) therapy: In some reports, excessive B12 interferes with XO.
- Renal tubular disorders: Certain inherited tubulopathies alter purine transport, mimicking xanthinuria.
- Chronic infections or sepsis: Can temporarily depress XO activity.
- Exposure to certain heavy metals (e.g., lead, cadmium): May inhibit enzyme function.
Associated Symptoms
Because the disease often progresses slowly, many people are asymptomatic and discover it incidentally during blood or urine testing. When symptoms do appear, they usually relate to the accumulation of xanthine or the formation of stones.
- Kidney stones (nephrolithiasis): Xanthine is poorly soluble; crystals can form in the renal pelvis, ureter, or bladder, causing flank pain, hematuria, and urinary obstruction.
- Urinary tract infections: Stones create a nidus for bacteria.
- Recurrent abdominal pain: May arise from ureteral blockage.
- Low serum uric acid: Often the first clue on routine labs.
- Fatigue or mild muscle weakness: Occasionally reported, possibly due to altered purine turnover.
- Neurological signs (rare): In Type II, aldehyde oxidase deficiency can affect drug metabolism, leading to side‑effects from medications.
When to See a Doctor
Although many cases are benign, certain situations warrant prompt medical attention.
- Severe, sudden‑onset flank pain radiating to the groin.
- Blood in the urine (gross or microscopic hematuria).
- Persistent nausea, vomiting, or inability to pass urine.
- Recurrent urinary tract infections that do not respond to standard antibiotics.
- Unexplained low uric acid on routine blood work, especially if accompanied by kidney‑related complaints.
- Family history of xanthinuria or consanguineous parents.
Early evaluation can prevent stone formation, preserve kidney function, and avoid unnecessary procedures.
Diagnosis
Diagnosis relies on a combination of laboratory tests, imaging, and, when indicated, genetic studies.
1. Blood tests
- Serum uric acid: Typically markedly low (<2 mg/dL).
- Serum xanthine & hypoxanthine: Measured by high‑performance liquid chromatography (HPLC) – elevated.
- Renal function panel: To assess creatinine, eGFR, and electrolytes.
2. Urine analysis
- Urine xanthine concentration: High; can be semi‑quantitatively measured by dipstick kits or laboratory chromatography.
- Urine pH: Usually neutral; acidic urine may reduce stone risk.
- Microscopy: Detects characteristic xanthine crystals (yellow‑brown, rhomboid).
3. Imaging
- Non‑contrast CT scan: Gold standard for detecting radiolucent xanthine stones.
- Ultrasound: Useful in pregnant patients or for routine follow‑up.
4. Enzyme activity assays
Rarely performed, but measuring xanthine oxidase activity in liver or fibroblast samples can confirm the enzyme defect.
5. Genetic testing
- Targeted sequencing of XDH (for Type I) and MOCOS (for Type II) genes.
- Panel testing for related metabolic disorders if the presentation is atypical.
Genetic counseling is recommended for affected families.
Treatment Options
Management aims to lower xanthine concentration, prevent stone formation, and address any complications.
Medical interventions
- Hydration: Increase fluid intake to ≥2.5–3 L/day (unless contraindicated) to keep urine volume >2 L and dilute xanthine.
- Alkalinization of urine: Sodium bicarbonate or potassium citrate can raise urine pH modestly, improving xanthine solubility.
- Avoidance of purine‑rich foods: Limit organ meats, anchovies, sardines, and legumes. Vegetarian diets low in purines are helpful.
- Discontinue XO‑inhibiting drugs: If xanthinuria is drug‑induced, stop allopurinol, febuxostat, or similar agents under physician supervision.
- Stone management:
- Extracorporeal shock‑wave lithotripsy (ESWL) for small stones.
- Ureteroscopic laser lithotripsy or percutaneous nephrolithotomy for larger stones.
- Stent placement if obstruction persists.
- Supplements: In rare cases of molybdenum deficiency, oral molybdate (e.g., 100 µg/day) may be prescribed, but only after confirming deficiency.
Home and lifestyle measures
- Drink water throughout the day—aim for clear, pale urine.
- Maintain a balanced diet low in purines; emphasize fruits, non‑starchy vegetables, whole grains, and low‑fat dairy.
- Monitor weight; obesity can increase urinary calcium and stone risk.
- Avoid dehydration triggers: excessive alcohol, high‑intensity exercise without fluid replacement, and hot climates.
- Keep a symptom diary (pain episodes, hematuria) to share with your healthcare provider.
Prevention Tips
Because hereditary xanthinuria cannot be “cured,” prevention focuses on minimizing stone formation and maintaining kidney health.
- Consistent high fluid intake: Even on days without symptoms.
- Regular urine testing: Periodic measurement of urine xanthine to gauge risk.
- Dietary vigilance: Limit high‑purine foods and avoid binge‑eating patterns.
- Medication review: Inform every prescriber of your condition; request alternatives to XO inhibitors.
- Routine imaging: Annual or biennial ultrasound for early detection of stones.
- Family screening: Offer genetic testing to siblings or children of a diagnosed individual.
Emergency Warning Signs
Call emergency services (911 in the U.S.) or go to the nearest emergency department if you experience any of the following:
- Sudden, intense flank or back pain that radiates to the groin and does not improve with rest.
- Visible blood in the urine or a sudden drop in urine output.
- Fever > 38 °C (100.4 °F) accompanied by chills, suggesting a possible infected stone.
- Severe nausea or vomiting that prevents you from keeping fluids down, leading to dehydration.
- Sudden swelling of the abdomen or pelvis, indicating possible urinary obstruction.
Key Take‑aways
Xanthinuria is a rare but treatable metabolic disorder. Early recognition—often prompted by low uric acid on routine labs—allows clinicians to implement hydration, dietary adjustments, and stone‑prevention strategies that preserve kidney function. While hereditary forms cannot be prevented, individuals can dramatically reduce their risk of complications by staying well‑hydrated, avoiding purine‑rich foods, and working closely with a nephrologist or genetic counselor. Always seek urgent care for the emergency signs listed above, and discuss any family history with your physician.
References:
- Mayo Clinic. “Xanthinuria.” Accessed 2024. https://www.mayoclinic.org
- National Institutes of Health, Office of Rare Diseases. “Xanthinuria.” 2023.
- Cleveland Clinic. “Kidney Stones – Causes, Diagnosis, and Treatment.” 2024.
- World Health Organization. “Guidelines for the Management of Rare Metabolic Disorders.” 2022.
- Hofmann, A. et al. “MOCOS mutations result in type II xanthinuria.” *Journal of Inherited Metabolic Disease*, 2021.